Schonfeld Strategic Advisors LLC Invests $6.12 Million in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Schonfeld Strategic Advisors LLC purchased a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 365,200 shares of the company's stock, valued at approximately $6,117,000. Schonfeld Strategic Advisors LLC owned approximately 0.28% of Centessa Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of CNTA. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after buying an additional 5,316 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Centessa Pharmaceuticals by 122.9% during the fourth quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after purchasing an additional 12,506 shares in the last quarter. Finally, Voya Investment Management LLC purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $497,000. 82.01% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the sale, the chief executive officer now owns 331,017 shares in the company, valued at approximately $5,273,100.81. The trade was a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David M. Chao sold 7,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now directly owns 225,007 shares in the company, valued at $3,863,370.19. This represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 202,353 shares of company stock worth $3,286,478. 11.59% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on CNTA shares. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating on the stock. Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley restated an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Piper Sandler started coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA traded up $0.17 on Wednesday, hitting $12.18. 151,334 shares of the company were exchanged, compared to its average volume of 617,810. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.62 billion, a P/E ratio of -7.94 and a beta of 1.53. The firm has a 50 day moving average of $14.07 and a two-hundred day moving average of $15.74. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. On average, equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.